2026 PharmDev Roadmap: The Strategic Partner

In the first three installments of this series, we explored the shifts redefining pharmaceutical development and manufacturing (PharmDev): supply chain fragmentation (Part 1), therapeutic modality complexity (Part 2), and the move toward predictive operating models (Part 3). Together, these pressures make clear that performance in PharmDev now depends on how effectively partnership networks are designed and orchestrated.

In 2026, the competitive advantage in PharmDev will increasingly come from how well organizations design and maintain their external execution networks.

The Strategic Partner – CDMOs as Strategic Partners in a Capacity-Constrained World

For a long time, scale and breadth were treated as indicators of strength in the CDMO market. Large organizations invested heavily in building broad capability portfolios across therapeutic modalities, development stages, and geographies, with the hope that they could offer a single solution to sponsors who preferred simplicity and centralized operations.

From a sponsor perspective, that approach had obvious advantages: it reduced coordination complexity, limited the number of contracts, and allowed a single organization to manage tech transfer, scale-up, and eventual commercial manufacturing under one umbrella. In a more stable operating environment, that structure worked well.

Operating conditions have since changed. As small molecules become more complex, biologics more analytical, and advanced therapies more intensive, technical requirements have diverged and maintaining equal depth across all of these domains is becoming more difficult. As the capital, talent, and operational focus required to cover such a vast range of capabilities increases, we are seeing an operational shift that favors networks of highly-specialized suppliers.

Building Your Network of Partners (for Sponsors)

For sponsors, this network-based operating model requires a different kind of discipline.

Partner selection is less about assembling a comprehensive capability list and more about understanding where genuine depth exists at specific points in the development timeline. It requires clarity about which parts of a program are technically sensitive and where handoffs are likely to introduce risk.

That discipline extends into how partners are vetted, as evaluating a CDMO now involves more than confirming stated capabilities, but includes a careful review of:

• Quality systems and data integrity practices
• Inspection history and compliance
• Containment strategy (when applicable)
• Analytical depth aligned to project complexity
• Realistic capacity at the required scale
• Scope alignment, technology platforms, and documentation maturity

Scope alignment, technology platforms, and an organization’s ability to execute consistently at the required scale are all key factors to consider. This means sponsors must be asking critical questions during consideration:

• Where does real experience sit for this modality at this scale?
• How compatible are quality systems between contributors?
• What assumptions are embedded in the process development package before it moves to another site?
• How realistic are proposed timelines given current capacity?
• If one partner slips, what downstream activities are affected?

Designing your partner network and qualifying those within it becomes a core element of execution strategy, but maintaining visibility, alignment, and coordination across the network is what ultimately determines performance.

Integrating into Partner Networks (for CDMOs)

For CDMOs, the environment demands clarity. This means being explicit about where the organization excels:

• Inspection history within a specific modality
• Containment strategy for highly potent compounds
• Analytical capability matched to complex biologics
• Operational experience at relevant scale

In a specialized environment, differentiation cannot remain implied — it must be visible. This is where structured GMP readiness assessments, clear technical documentation, and strong marketing plans become valuable.

• Pre-assessment programs allow suppliers to demonstrate compliance maturity before formal audits begin – making them standout contenders for sponsor contracts.
• Complete technical documentation allows potential sponsor partners to discover and evaluate capabilities upfront.
• Thoughtful marketing and brand awareness campaigns allow new and existing partners to discover, understand, consider, and contract your complex technologies.

In this context, integrating into a network requires demonstrating your capabilities and making sure you’re a leading, proactive voice in your segment of the industry.

Sourcing as Orchestration

As partnerships become more distributed, sourcing strategies become more demanding. While the days of relying on a single supplier are largely behind us, the industry is leveraging new approaches to maintain centralized operations across increasingly distributed networks.

When programs rely on multiple specialized CDMOs, performance depends on how deliberately those partners are identified, compared, qualified, and maintained over time. The strength of the network begins with the sourcing discipline applied before technical work even starts. Traditional sourcing processes were built around sequential evaluation: identify a supplier, exchange documentation, conduct qualification, then move forward. In a modality-specialized environment, that linear approach slows decision cycles and obscures meaningful differences in technical depth.

Sponsors increasingly need to evaluate multiple specialized suppliers in parallel, compare capabilities on a structured basis, and maintain visibility into qualified partners beyond a single engagement. Without standardization, that comparison becomes interpretive rather than analytical.

Orchestration, in this context, means introducing structure at each stage of partner engagement:

• Discovery of technically aligned suppliers
• Standardized presentation of capability and infrastructure depth
• Centralized GMP pre-assessment to inform qualification readiness
• Side-by-side comparison across defined evaluation criteria
• Ongoing visibility into approved and previously qualified partners

Scientist.com addresses this challenge by providing a centralized platform for supplier discovery, standardized documentation, GMP pre-assessments, and structured network maintenance. Sponsors gain earlier, continuous, and more reliable visibility into the full landscape of CDMOs and can evaluate multiple qualified options in parallel, thus compressing decision cycles and reducing repetitive evaluation.

For CDMOs, this connected structure offers a unique channel to present documentation, technical depth, and verified compliance. In a fragmented sourcing landscape, visibility through a unified channel allows organizations to establish themselves as credible partners across sponsor programs through both documented capabilities and point-of-purchase marketing channels.

In today’s distributed sourcing model, resilience depends on disciplined network orchestration, and that is exactly the layer Scientist.com is built to support.

Looking Ahead: The Regulatory Dimension

As development networks become more distributed, regulatory expectations intensify. Regulators increasingly expect clear process understanding, consistent data integrity, and well-documented change management across the lifecycle of a product. When multiple CDMOs are involved, that expectation extends across organizations and sponsors must demonstrate not only that each partner meets GMP standards, but that the overall development strategy is coherent and defensible.

In the final installment of this series, we will examine evolving FDA and EMA expectations and what this means for both sponsors and their networks of partners.

Next in the series: The Regulatory Shift: FDA and EMA expectations for new modalities.